.
MergerLinks Header Logo

New Deal


Announced

Completed

RA Capital Management and Andera Partners led a $118m Series B round in Mineralys Therapeutics.

Financials

Edit Data
Transaction Value£94m
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

United States

Biotechnology

life sciences

Minority

Acquisition

Cross Border

Friendly

Single Bidder

Private Equity

Venture Capital

Private

Completed

Synopsis

Edit

RA Capital Management, a multi-stage investment manager company, and Andera Partners, an asset management firm, led a $118m Series B round in Mineralys Therapeutics, a private, clinical-stage biopharmaceutical company, with participation from RTW Investments, Rock Springs Capital, SR One Capital Management, Sectoral Asset Management, Ysios Capital, HealthCor Management, Boulder Ventures, Catalys Pacific, Samsara BioCapital, HBM Healthcare Investments and Adams Street Partners. “We are excited to have co-led this financing with Andera partners and look forward to helping Mineralys progress on the promise of MLS-101 for the treatment of hypertension,” Derek DiRocco, RA Capital Management Partner.

Search a database of more than 250,000 verified dealmakers

Receive automated updates on global transactions

Follow the activity, relationships and transactions of top dealmakers

No credit card required

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US